Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rationale for a nanomedicine approach to thrombolytic therapy.

Literature DB >> 20876503

Rationale for a nanomedicine approach to thrombolytic therapy.

Gregory M Lanza¹, Jon N Marsh, Grace Hu, Michael J Scott, Anne H Schmieder, Shelton D Caruthers, Dipanjan Pan, Samuel A Wickline.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2010 PMID： 20876503 PMCID： PMC2953722 DOI： 10.1161/STROKEAHA.110.598656

Source DB: PubMed Journal: Stroke ISSN： 0039-2499 Impact factor: 7.914

× No keyword cloud information.

30 in total

Review 1. Microbubbles for thrombolysis of acute ischemic stroke.

Authors: Stephen Meairs; William Culp
Journal: Cerebrovasc Dis Date: 2009-04-16 Impact factor: 2.762

2. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial.

Authors: Carlos A Molina; Andrew D Barreto; Georgios Tsivgoulis; Paul Sierzenski; Marc D Malkoff; Marta Rubiera; Nicole Gonzales; Robert Mikulik; Greg Pate; James Ostrem; Walter Singleton; Garen Manvelian; Evan C Unger; James C Grotta; Peter D Schellinger; Andrei V Alexandrov
Journal: Ann Neurol Date: 2009-07 Impact factor: 10.422

3. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques.

Authors: S Flacke; S Fischer; M J Scott; R J Fuhrhop; J S Allen; M McLean; P Winter; G A Sicard; P J Gaffney; S A Wickline; G M Lanza
Journal: Circulation Date: 2001-09-11 Impact factor: 29.690

4. Targeting of alpha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles.

Authors: Walter J Akers; Zongren Zhang; Mikhail Berezin; Yunpeng Ye; Anthony Agee; Kevin Guo; Ralph W Fuhrhop; Samuel A Wickline; Gregory M Lanza; Samuel Achilefu
Journal: Nanomedicine (Lond) Date: 2010-07 Impact factor: 5.307

5. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.

Authors: J N Marsh; A Senpan; G Hu; M J Scott; P J Gaffney; S A Wickline; G M Lanza
Journal: Nanomedicine (Lond) Date: 2007-08 Impact factor: 5.307

6. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.

Authors: Patrick M Winter; Shelton D Caruthers; Huiying Zhang; Todd A Williams; Samuel A Wickline; Gregory M Lanza
Journal: JACC Cardiovasc Imaging Date: 2008-09

7. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.

Authors: Anne H Schmieder; Shelton D Caruthers; Huiying Zhang; Todd A Williams; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal: FASEB J Date: 2008-08-12 Impact factor: 5.191

8. Simulation of intracranial acoustic fields in clinical trials of sonothrombolysis.

Authors: Cecile Baron; Jean-François Aubry; Mickael Tanter; Stephen Meairs; Mathias Fink
Journal: Ultrasound Med Biol Date: 2009-04-25 Impact factor: 2.998

9. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.

Authors: Patrick M Winter; Anne H Schmieder; Shelton D Caruthers; Jeffery L Keene; Huiying Zhang; Samuel A Wickline; Gregory M Lanza
Journal: FASEB J Date: 2008-03-24 Impact factor: 5.191

10. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model.

Authors: Michal Lijowski; Shelton Caruthers; Grace Hu; Huiying Zhang; Michael J Scott; Todd Williams; Todd Erpelding; Anne H Schmieder; Garry Kiefer; Gyongyi Gulyas; Phillip S Athey; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal: Invest Radiol Date: 2009-01 Impact factor: 6.016

9 in total

Review 1. Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors: Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal: Nat Rev Drug Discov Date: 2011-10-21 Impact factor: 84.694

2. Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis.

Authors: Christa L Pawlowski; Wei Li; Michael Sun; Kavya Ravichandran; DaShawn Hickman; Clarissa Kos; Gurbani Kaur; Anirban Sen Gupta
Journal: Biomaterials Date: 2017-03-14 Impact factor: 12.479

3. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

Authors: Shan Liu; Xiaozhou Feng; Rong Jin; Guohong Li
Journal: Expert Opin Drug Deliv Date: 2017-09-28 Impact factor: 6.648

Review 4. Advanced drug delivery systems for antithrombotic agents.

Authors: Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal: Blood Date: 2013-06-24 Impact factor: 22.113

Review 5. Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives.

Authors: Natasha Manners; Vishnu Priya; Abhishesh Kumar Mehata; Manoj Rawat; Syam Mohan; Hafiz A Makeen; Mohammed Albratty; Ali Albarrati; Abdulkarim M Meraya; Madaswamy S Muthu
Journal: Pharmaceuticals (Basel) Date: 2022-04-01

9. Copper-Catalyzed Syntheses of Pyrene-Pyrazole Pharmacophores and Structure Activity Studies for Tubulin Polymerization.

Authors: Dinabandhu Sar; Indrajit Srivastava; Santosh K Misra; Fatemeh Ostadhossein; Parinaz Fathi; Dipanjan Pan
Journal: ACS Omega Date: 2018-06-13